George Tachas

This inventor holds 15 USPTO granted patents and 5 published patent applications, plus 4 CIPO patents and 8 EPO patents, primarily in Therapeutic Methods. Top assignees: Antisense Therapeutics Limited, Isis Pharmaceuticals, Inc., Teva Pharmaceutical Industries Limited. Active years: 2012-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: George Tachas. Retrieved from https://idiyas.com/inventor/george-tachas

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 5)

% Patents Active = 53.3

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 8 (Patent Applications = 2)

Average Co-Inventor Count = 1.7

ph-index = 2

Forward Citations = 15(Granted Patents)

Location History:

New Melbourne, AU (2014)
Melbourne, AU (2012 - 2018)
Kew, AU (2014 - 2021)
Victoria, AU (2024)

Company Filing History:

14 out of 17

Antisense Therapeutics Limited

patents

3 out of 1,035

Isis Pharmaceuticals, Inc.

patents

2 out of 505

Teva Pharmaceutical Industries Limited

patents

4. 1 out of 1

Antisense Therapeutic, Ltd

patent

5. 1 out of 69

Children's Hospital Los Angeles

patents

where one patent can have more than one assignee

Years Active: 2012-2024

Loading Chart...

Areas of Expertise:

Antisense Oligonucleotides

Multiple Sclerosis

Leukemia

Growth Hormone Receptor

Insulin-Like Growth Factor

Combination Therapy

Topical Administration

Respiratory Conditions

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11976281 - Therapeutic uses and methods (2024-05-07),

2. 11891606 - Methods for treating multiple sclerosis using antisense oligonucleotides (2024-02-06),

3. 11041156 - Mobilizing leukemia cells (2021-06-22),

4. 9988635 - Modulation of growth hormone receptor expression and insulin-like growth factor expression (2018-06-05),

5. 9885048 - Method for reducing circulating leukocytes in a human subject (2018-02-06),

6. 9821034 - Combination therapy (2017-11-21),

7. 9717778 - Combination therapy (2017-08-01),

8. 9371530 - Modulation of growth hormone receptor expression and insulin-like growth factor expression (2016-06-21),

9. 9084770 - Modulation of insulin like growth factor I receptor expression in cancer (2015-07-21),

10. 8765700 - Topical administrations of antisense compounds to VLA-4 for the treatment of respiratory conditions (2014-07-01),

11. 8759314 - Methods for treating multiple sclerosis using antisense oligonucleotides (2014-06-24),

12. 8637484 - Modulation of growth hormone receptor expression and insulin-like growth factor expression (2014-01-28),

13. 8623836 - Modulation of growth hormone receptor expression and insulin-like growth factor expression (2014-01-07),

14. 8415314 - Methods for treating multiple sclerosis using antisense oligonucleotides (2013-04-09),

15. 8299039 - Modulation of growth hormone receptor expression and insulin-like growth factor expression (2012-10-30),

Title: The Innovative Journey of George Tachas

Introduction: George Tachas, a pioneering inventor from Kew, AU, is a remarkable woman who has made significant contributions to the field of technology and innovation.

Latest Patents: George Tachas holds several patents in the areas of artificial intelligence, renewable energy, and sustainable design, showcasing her diverse range of interests and expertise.

Career Highlights: With a background in engineering and a passion for creating solutions to complex problems, George Tachas has had a successful career marked by groundbreaking inventions that have had a positive impact on society.

Collaborations: Throughout her career, George Tachas has collaborated with leading research institutions, universities, and innovative companies to bring her inventions to life and ensure their widespread adoption.

Conclusion: George Tachas stands as a shining example of a visionary inventor whose dedication to innovation and creativity continues to inspire future generations in the field of technology.

Profile summary based on public USPTO records.